vTv Therapeutics (VTVT) Current Deferred Revenue (2015 - 2026)

vTv Therapeutics has disclosed Current Deferred Revenue across 12 years of filings, most recently posting $1.3 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $1.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY), and the FY2025 annual result was $18.7 million, changed 0.17% from the prior year.
• Current Deferred Revenue came in at $1.3 million for Q1 2026 at vTv Therapeutics, down from $18.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $18.7 million in Q4 2025 to a low of $17000.0 in Q4 2022.
• The 5-year median for Current Deferred Revenue is $17000.0 (2022), against an average of $5.4 million.
• Across the five-year window, Current Deferred Revenue plunged 99.91% in 2023 and jumped 109717.65% in 2024, its largest moves.
• vTv Therapeutics' Current Deferred Revenue stood at $17000.0 in 2022, then changed by 0.0% to $17000.0 in 2023, then surged by 109717.65% to $18.7 million in 2024, then advanced by 0.17% to $18.7 million in 2025, then tumbled by 93.05% to $1.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.3 million (Q1 2026), $18.7 million (Q4 2025), and $18.7 million (Q4 2024), per Business Quant data.